Top 9 onco-myths

In this article we will dispel 9 common oncomyphs.
Myth #1: Cancer treatment is harder than cancer itself!

In most cases, the treatment of oncological diseases is complex. That is, it consists of several stages: surgery / radiation therapy / drug therapy.
Yes, the treatment can be long, but thanks to this, the disease goes into remission.

Myth #2: Deodorants, antiperspirants and so on lead to cancer.

Non-use of antiperspirants / deodorants leads to an unpleasant smell of the armpits, but certainly not to cancer.

Myth #3: Smartphones emit cancer.

Then why was cancer before smartphones?
And why, with the advent of these technical devices, the number of oncological diseases has not increased by 1000 times? Smartphones are not a source of cancer.

Myth #4: After radiation therapy/CT/PET/MRI/X-ray, a person becomes radioactive.

With all these studies, the radiation load is so low that you will have to be examined 24/7 for about 70 years to start emitting radiation. And then it is no longer known from what will die earlier - from radiation exposure or from old age.

Myth #5: If my great-grandmother had cancer, then so will I.

Hereditary syndromes occur in 5-10% of cases. Basically, this is our dismissive attitude to lifestyle.

Myth #6: Cancer can be cured by bodily practices.

Bodily practices can do a lot of things. Improve your mental health, sit on the splits and put your leg behind your ear, but you can't cure cancer.

Myth #7: People have never had cancer before.

There were even special types of cancer that are not there now. For example, scrotal cancer. This oncodiagnosis was found only in chimney sweeps!

Myth #8: Sugar provokes cancer.

Sugar is the cause of tooth decay and obesity.
But obesity is a risk factor for cancer. That is, it's about the amount of sugar, not sugar as such.

Myth #9: A benign tumor can become cancer.

A benign tumor can live in every organ, and not every one of them can turn into cancer.
Subscribe to the newsletter or ask a question
Click to order
Your order
Step #1:Leave contact details for delivery and feedback.
Step #2: After adding contacts, you will be taken to the Stripe payment page, where you can pay for mole tracker and delivery in two clicks.
Your Name
Your Email
Your Phone
On the day of payment, we transmit the information to the delivery service. The delivery time to residents of the USA is 3 days, for the whole world - 14-19 days, depending on the recipient's address.
List of literature
  1. Lomas A., Leonardi-Bee J., Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166: 1069–80.
  2. Karjalainen S1, Salo H., Teppo L. Basal cell and squamous cell carcinoma of the skin in Finland. Site distribution and patientsurvival. Int J Dermatol. 1989 Sep; 28(7): 445–50.
  3. Bastiaens MT, Hoefnagel JJ, Bruijn JA et al. Differences in age, site distribution, and sex between nodular and superficial basal cell carcinoma indicate different types of tumors. J Invest Dermatol 1998; 110:880–4.
  4. Luz FB, Ferron C., Cardoso GP. Surgical treatment of basal cell carcinoma: an algorithm based on the literature. An Bras Dermatol. 2015 May-Jun; 90(3): 377–83.
  5. Julien Lanoue, Gary Goldenberg. Basal Cell Carcinoma, А Comprehensive Review of Existing and Emerging Nonsurgical Therapies. J Clin Aesthet Dermatol. 2016 May; 9 (5): 26–36.]
  6. Vijlder, H., Sterenborg, H., Neumann, H., Robinson, D., Haas, E. (2012). Light Fractionation Significantly Improves the Response of Superficial Basal Cell Carcinoma to Aminolaevulinic Acid Photodynamic Therapy: Five-year Follow-up of a Randomized, Prospective Trial. Acta Dermato Venereologica, 92 (6), 641–647. doi: 10.2340/00015555-1448
  7. Lehmann, P. (2007). Methyl aminolaevulinate?photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. British Journal of Dermatology, 156(5), 793–801. doi: 10.1111/j.1365-2133.2007.07833.x.
  8. Ceilley RI, Del Rosso JQ. Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol. 2006 May; 45(5): 489–98.
  9. Wysong, A., Aasi, S. Z., Tang, J. Y. (2013). Update on Metastatic Basal Cell Carcinoma: A Summary of Published Cases From 1981 Through 2011. JAMA Dermatology, 149(5), 615.
  10. Sekulic A, Migden MR, Basset-Seguin N., Garbe C., Gesierich A., Lao CD., Miller C., Mortier L., Murrell DF., Hamid O., Quevedo JF., Hou J., McKenna E., Dimier N., Williams S., Schadendorf D., Hauschild A.; ERIVANCE BCC Investigators.Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: finalupdate of the pivotal ERIVANCE BCC study. BMC Cancer. 2017 May 16; 17(1):3 32. doi: 10.1186/s12885-017-3286-5.
  11. Lear JT., Migden MR., Lewis KD., Chang ALS., Guminski A., Gutzmer R., Dirix L., Combemale P., Stratigos A., Plummer R., Castro H, Yi T., Mone M., Zhou J., Trefzer U., Kaatz M., Loquai C., Kudchadkar R., Sellami D., Dummer R. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.J Eur Acad Dermatol Venereol. 2018 Mar; 32 (3): 372–381. doi: 10.1111/jdv.14542. Epub 2017 Nov 6.
  12. Wieman TJ., Shively EH., Woodcock TM. Responsiveness of metastatic basal-cell carcinoma to chemotherapy. A case report. Cancer. N1983; 52 (9): 1583–1585.
  13. Coker DD, Elias EG, Viravathana T, et al. Chemotherapy for metastatic basal cell carcinoma. Arch Dermatol. 1983; 119 (1): 44–50.
  14. Guthrie TH., Jr, McElveen LJ., Porubsky ES., Harmon JD. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985; 55 (8): 1629–1632.
  15. Bason MM., Grant-Kels JM., Govil M. Metastatic basal cell carcinoma: response to chemotherapy. J Am Acad Dermatol. 1990; 22 (5 Pt 2): 905–908.
  16. Khandekar JD. Complete response of metastatic basal cell carcinoma to cisplatin chemotherapy: a report of two patients. Arch Dermatol. 1990; 126 (12): 1,660.
  17. Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999; 22 (1): 32–34.
  18. Jefford M., Kiffer JD., Somers G., et al. Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg. 2004; 74 (8): 704–705.
  19. Moeholt K., Aagaard H., Pfeiffer P., Hansen O. Platinum-based cytotoxic therapy in basal cell carcinoma-a review of the literature. Acta Oncol. 1996; 35 (6): 677–682.
  20. Carneiro BA., Watkin WG., Mehta UK., Brockstein BE. Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Invest. 2006; 24 (4): 396–400.